A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia (NCT06173570), a randomized phase 2 study. The primary outcome is Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12.

2. Clinical Question

3. Trial Design

This was a Phase IIb, multicenter, randomized, parallel-group, double-blind, placebo-controlled, dose-ranging study of AZD0780 in participants with dyslipidemia. The registry identifies the masking as quadruple. The dose groups received AZD0780 1 mg, 3 mg, 10 mg, or 30 mg daily; the comparator received placebo matched for appearance. The registry enrollment was 428.

The primary outcome was percent change in LDL-C from baseline through week 12. Baseline was defined as the last non-missing value before the first administration of study treatment. The primary hypothesis stated that at least one investigated dose would be superior to placebo for lowering LDL-C over that period. The registry also lists secondary lipid outcomes, including total cholesterol, HDL-C, triglycerides, non-HDL-C, VLDL-C, apolipoprotein A1, and apolipoprotein B. Inflammatory markers, AZD0780 blood concentrations, safety, and tolerability were also study objectives.

The registry records the study as completed, with a start date of 2024-01-19 and a primary completion date of 2024-09-30. It states that follow-up occurred after the end of treatment. Details of the follow-up schedule and duration are not reported in the registry record. The record does not report the method used to generate the randomization sequence, how allocation was concealed, or which roles were included in quadruple masking. It also does not report the number of clinical centers.

The primary analysis population was the Full Analysis Set, defined as all randomized participants who received at least one dose of study treatment. The registry enrollment and the analysis-population definition describe different things: enrollment is a trial-level figure, while the definition specifies who was included in the primary analysis. Arm-specific numbers analyzed are reported alongside the endpoint results.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Of 428 enrolled participants, two randomized participants - one screen failure and one withdrawal by subject - did not start treatment.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Full Analysis Set: all randomized participants who received at least one dose of study treatment.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12, measured over From first day of treatment up to week 12.

The primary endpoint was percent change in LDL-C from baseline to week 12. LDL-C is a lipid measure, and the study used its change over the treatment period as the principal measure for comparing AZD0780 doses with placebo. The registry defines percent change as the week 12 LDL-C value minus baseline LDL-C, divided by baseline LDL-C, multiplied by 100. Negative values indicate a reduction. The outcome is reported as a least-squares mean with a 95% confidence interval.

Using percent change expresses the change relative to each participant’s baseline value rather than in the original LDL-C measurement units. This can make changes easier to compare across participants whose starting values differ. In general, a model-based mean summarizes the endpoint while accounting for the statistical model used in the analysis; the registry does not report the model’s covariates or other specification details.

The endpoint timeframe was from the first day of treatment up to week 12. The registry describes a hypothetical estimand: data collected after intercurrent events defined in the CSP were excluded. The particular events and the procedures used to address missing values are not reported in the registry record. The endpoint therefore describes the specified analysis of LDL-C change, not every possible way of defining or analyzing outcomes after treatment-related events.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The primary outcome is continuous: it is percent change in LDL-C, and its registry parameter is the least-squares mean. The results include arm-specific estimates and 95% confidence intervals, followed by sponsor-reported mixed-model comparisons against placebo. These answer related but distinct descriptive and inferential questions. The arm estimates characterize the modeled endpoint within each group; a net mean difference describes a modeled contrast between a dose group and placebo.

What does a least-squares mean represent?

In general, a least-squares mean is a mean estimated from a statistical model rather than a simple arithmetic average of the observed values. Its interpretation depends on the model and the terms included in it. The registry identifies the primary parameter as a least-squares mean but does not report the covariates, repeated-measures structure, or other model details. It is therefore not possible to reconstruct the precise adjustment or modeling assumptions from the registry record alone.

The reported dose-specific estimates are -31.19 for 1 mg, -33.83 for 3 mg, -41.09 for 10 mg, and -46.62 for 30 mg. The placebo estimate is 4.08. Because negative endpoint values denote reductions in LDL-C, the sign is important when interpreting these estimates. The 95% confidence intervals express uncertainty around each estimate under the analysis used; they do not show the range of individual participant responses.

How should the mixed-model contrasts be read?

The sponsor reported a mixed-model mean difference, labeled as a net difference, for each dose versus placebo. The estimates were -35.27 for 1 mg, -37.91 for 3 mg, -45.17 for 10 mg, and -50.70 for 30 mg. Each was accompanied by a 95% confidence interval and p < 0.001. On the endpoint scale, a negative contrast is in the direction of a larger reduction in the dose group than in placebo. The registry identifies these as superiority comparisons.

In general, a mixed model can represent relationships among outcome measurements and can use model assumptions to estimate group means or contrasts. It does not automatically correct every source of bias, and its validity depends on specification and assumptions. The registry does not report enough detail to evaluate the model structure, covariance assumptions, or how values unavailable at week 12 were handled. The sponsor’s reported estimates and tests should be interpreted within that limitation.

What does the confidence interval add?

A confidence interval communicates precision as well as direction. In general, a narrower interval indicates greater precision under the specified model, whereas a wider interval reflects more uncertainty about the estimate. An interval should not be read as containing a fixed proportion of individual participants’ outcomes. The interval also does not account automatically for multiplicity unless the analysis method explicitly incorporates it; such an adjustment is not reported in the registry record.

The p-values are reported as p < 0.001 for all dose-versus-placebo comparisons. In general, a p-value evaluates the compatibility of the data with a null hypothesis under the model assumptions. It is not a measure of effect size, clinical importance, or the probability that a result occurred by chance. The confidence intervals and estimated differences give information about magnitude and uncertainty that a p-value alone does not provide.

What is the role of the analysis population and estimand?

The Full Analysis Set included randomized participants who received at least one dose of study treatment. This is the registry’s stated population for the primary outcome. The hypothetical estimand excludes data collected after intercurrent events defined in the CSP. In general, an estimand specifies the treatment effect a trial aims to estimate, including how events after treatment begins are handled. Excluding post-event observations gives the analysis a particular interpretation; it is not equivalent to including every outcome regardless of such events.

The registry record does not report the specific intercurrent events, the amount or pattern of missing endpoint data, or the missing-data method. It also does not report the full statistical analysis plan. These omissions limit independent assessment of how the model and estimand were implemented. Planning sample sizes calculated from observed effects are illustrations based on assumptions, not observed trial results or evidence of power achieved in this trial.

10. Analyses Reported by the Sponsor

The registry’s sponsor-reported primary comparisons use mixed models and report a net mean difference for each AZD0780 dose versus placebo, with a 95% confidence interval and p < 0.001 for every comparison. These are the inferential comparisons to use when describing the sponsor’s analysis. They should not be confused with the individual least-squares mean estimates for each group.

A simple recalculation from posted arm-level summaries is unadjusted. In general, it cannot be expected to reproduce a model-based contrast if the sponsor’s model includes features not represented in those summaries. The registry record does not report numerical recalculated contrasts separately. It flags no discrepancy between the sponsor results and the recalculation. Where a discrepancy is flagged, the sponsor’s own analysis takes precedence; that qualification is not triggered by the record for this trial.

Interpretation should retain the distinction between the posted endpoint summaries and the sponsor’s mixed-model tests. The registry does not report the detailed model specification needed to reproduce the sponsor analysis independently.

11. Multiplicity, Missing Data and Analysis Populations

The primary hypothesis was that at least one investigated AZD0780 dose would be superior to placebo for the LDL-C endpoint. The registry reports a separate sponsor comparison for each dose versus placebo. Testing multiple dose comparisons raises a multiplicity question: in general, repeated testing can increase the chance of at least one apparently positive result when all null hypotheses are true. The registry record does not report whether a multiplicity adjustment or a prespecified testing sequence was used. The reported p-values should therefore be described as posted, without assuming that family-wise error was controlled.

The record lists 20 outcome measures and 64 analyses, and it identifies 19 posted secondary outcomes. The presence of multiple endpoints and analyses makes it especially important to know which tests were confirmatory, how they were ordered, and whether adjustments were made. Those details are not reported in the registry record. It is also not reported whether interim analyses occurred or whether the sample size was justified by a prespecified power calculation.

The primary analysis population was the Full Analysis Set, defined as all randomized participants who received at least one dose. The primary endpoint used a hypothetical estimand that excluded data collected after intercurrent events defined in the CSP. The registry does not identify those events, explain how participants with such events were handled beyond the stated exclusion, or describe methods for missing week 12 measurements. It does not report the amount or reasons for missing data, sensitivity analyses, or whether other estimands were examined.

In general, missing-data assumptions can influence model estimates when outcomes are unavailable, and sensitivity analyses can help assess dependence on those assumptions. Without the analysis details, the registry results cannot establish how robust the findings are to alternative missing-data assumptions. These gaps do not change the reported estimates; they limit the ability to evaluate how they were produced and how broadly they apply.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: osteomyelitis (1.2%), lentigo maligna (1.2%), colonic abscess (1.2%), transient ischaemic attack (1.2%), inguinal hernia (1.2%).

The registry reports serious adverse events among participants at risk in each group. The counts affected were 2 for AZD0780 1 mg, 2 for 3 mg, 2 for 10 mg, 1 for 30 mg, and 0 for placebo. Other adverse events were reported for 4, 2, 2, 3, and 5 participants in those respective groups. The registry reports zero deaths in every group. These are counts, not measures of event severity beyond the serious-event classification, and they do not describe the nature of all events.

The listed serious-event terms are osteomyelitis, lentigo maligna, colonic abscess, transient ischaemic attack, inguinal hernia, and Major Depression, each shown as 1.2%. The registry record does not report arm-specific attribution for these terms in the information available for this summary. The term list should not be interpreted as a complete clinical description of the events or as evidence about causality.

In general, safety counts are descriptive. Comparisons across groups require attention to the number at risk, exposure time, event definitions, and the possibility of chance variation. The registry reports group-specific numbers at risk, but does not provide exposure-adjusted rates or enough event detail to assess timing, recurrence, or relationship to treatment. These figures alone do not establish whether an event was caused by study treatment, nor do they characterize safety beyond the reported observation period.

13. What the Result Does, and Does Not, Mean

The posted results show negative modeled mean percent changes in LDL-C for each AZD0780 dose group and a positive estimate for placebo. The sponsor’s mixed-model comparisons report negative net differences versus placebo for every dose, with 95% confidence intervals entirely below zero and p < 0.001. These findings describe the registry’s primary endpoint analysis through week 12 in the stated analysis population and under the stated hypothetical estimand.

They do not establish that every participant had a reduction, because group means do not describe each individual outcome. They do not show that all participants completed treatment or had an observed week 12 measurement. The registry does not report missing-data details or enough model specification to reconstruct the analysis independently. Nor do these endpoint results establish effects on clinical events, long-term outcomes, or measures not reported in the posted results.

Statistical evidence against a null comparison is not the same as evidence of clinical importance. The registry results describe differences on the percent-change scale; no threshold for a clinically meaningful change is reported. The primary endpoint is LDL-C, and the results should not be extended to other lipid parameters or inflammatory markers without examining their own outcome estimates and analyses.

The results also do not resolve uncertainty about multiplicity. The registry lists multiple outcomes and analyses but does not report whether the sponsor adjusted for multiple comparisons. Likewise, the reported adverse-event counts are descriptive and cannot establish causation or fully characterize safety. A rounded summary of outcome estimates is useful for reading the statistical result, but it is not a complete account of every design, analysis, and safety detail.

14. Why This Trial Matters Statistically

This trial is statistically informative because it evaluates multiple AZD0780 dose levels against a placebo comparator using a continuous LDL-C endpoint. The dose-specific estimates and corresponding placebo comparison make it possible to examine the direction and precision of the modeled changes across dose groups. The sponsor’s mixed-model contrasts add formal comparisons to the group estimates.

The trial also illustrates why endpoint definitions matter. Percent change is relative to baseline, negative values indicate reduction, and the primary analysis uses a least-squares mean rather than a simple mean. The hypothetical estimand further specifies that observations after defined intercurrent events are excluded. Each choice shapes the interpretation of the result; readers need the endpoint scale, analysis population, and estimand to understand what the reported estimate represents.

The record also highlights questions that accompany dose-ranging analyses. Multiple dose-versus-placebo comparisons and a range of outcomes raise issues of multiplicity and selective interpretation. Although the registry lists outcome and analysis counts, the multiplicity strategy is not reported. Similarly, model specifications and missing-data procedures are not described in enough detail for a full independent evaluation. These are important statistical considerations even when the sponsor-reported comparisons are clear.

Finally, the reported confidence intervals communicate precision for the primary outcome, while the adverse-event counts provide a separate, descriptive view of safety. Neither should be treated as a complete account of treatment effects. The trial’s statistical contribution is the set of estimated changes and comparisons under its stated design and analysis, together with the questions left open by the registry record.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several trial-specific reporting gaps constrain interpretation. The registry does not report the detailed statistical model used for the least-squares means and mixed-model contrasts, including covariates, covariance structure, or other model terms. Consequently, readers cannot fully reproduce the sponsor’s analysis from the record or assess every modeling assumption.

The record describes a hypothetical estimand that excludes post-intercurrent-event data, with events defined in the CSP, but does not identify those events in the information available for this summary. Missing-data methods, the number and reasons for unavailable endpoint observations, and sensitivity analyses are not reported in the registry record. The implications of those choices for the endpoint estimates cannot be assessed from the reported summaries alone.

The registry reports multiple outcomes and analyses but does not report a multiplicity strategy. It also does not report an interim-analysis plan or a sample-size justification. Planning illustrations based on observed effects should not be mistaken for the trial’s original design rationale or for observed power.

The safety information includes group-level counts but limited event detail. The record does not provide exposure-adjusted safety rates, timing and duration for events, or arm-specific attribution for the listed serious-event terms in the information available for this summary. The results therefore provide a limited descriptive account rather than a complete assessment of event patterns or causality.

Other design details, including the randomization procedure, allocation concealment, and the roles covered by quadruple masking, are not reported in the registry record. The registered enrollment does not by itself explain the number contributing to each outcome analysis. These limits qualify independent appraisal without changing the values the registry reports.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia — NCT06173570.
• Registry record last updated 2025-11-17; status last verified 2025-11.
• Results first posted 2025-11-17.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry record describes a completed Phase IIb, multicenter, randomized, parallel-group, double-blind, placebo-controlled, dose-ranging study of AZD0780 in participants with dyslipidemia. The recorded enrollment was 428. The study began on 2024-01-19 and had a primary completion date of 2024-09-30.

The primary endpoint was percent change in LDL-C from baseline through week 12. The record reports least-squares mean estimates for AZD0780 1 mg, 3 mg, 10 mg, and 30 mg and placebo, alongside sponsor mixed-model comparisons of each dose with placebo. The sponsor reported p < 0.001 for each comparison. The primary analysis population was the Full Analysis Set, and the specified hypothetical estimand excluded post-event data as described in the registry.

Safety summaries report serious and other adverse-event counts and zero deaths across the listed groups. Details of multiplicity adjustment, missing-data procedures, and full model specification are not reported in the registry record.